ALK and non-small cell lung carcinoma: By studying both the effects of short term and long term crizotinib treatment on ALK+ NSCLC cells to IGF-1R sensitivity we aimed to determine the independence of ALK and IGF-1R as drug targets both with respect to innate and acquired crizotinib resistance.